Could really go either way. They could be trying to figure out what’s gone wrong or results are better than expected and they want time to write something to publish. I’d be annoyed if all the time and money that’s been deployed for the phase 1b was all for nothing, but then why would they bother if they weren’t seeing decent results? I dunno but could be an interesting end to the year.
Clinical Trials, page-12
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
